Ngiow SF - Search Results

1

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Gao Y, et al. Among authors: ngiow sf. Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31. Nat Immunol. 2017. PMID: 28759001

2

Does IL-17 suppress tumor growth?

Ngiow SF, Smyth MJ, Teng MW. Ngiow SF, et al. Blood. 2010 Mar 25;115(12):2554-5; author reply 2556-7. doi: 10.1182/blood-2009-11-254607. Blood. 2010. PMID: 20339108 Free article. No abstract available.

3

IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.

Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Möller A, Hill GR, Iwakura Y, Oft M, Smyth MJ. Teng MW, et al. Among authors: ngiow sf. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8328-33. doi: 10.1073/pnas.1003251107. Epub 2010 Apr 19. Proc Natl Acad Sci U S A. 2010. PMID: 20404142 Free PMC article.

4

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T. Klages K, et al. Among authors: ngiow sf. Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20924102

5

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Teng MW, et al. Among authors: ngiow sf. Cancer Res. 2010 Oct 15;70(20):7800-9. doi: 10.1158/0008-5472.CAN-10-1681. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20924111

6

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Ngiow SF, et al. Cancer Res. 2011 May 15;71(10):3540-51. doi: 10.1158/0008-5472.CAN-11-0096. Epub 2011 Mar 23. Cancer Res. 2011. PMID: 21430066

7

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Stagg J, et al. Among authors: ngiow sf. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7. doi: 10.1073/pnas.1016569108. Epub 2011 Apr 11. Proc Natl Acad Sci U S A. 2011. PMID: 21482773 Free PMC article.

8

Prospects for TIM3-Targeted Antitumor Immunotherapy.

Ngiow SF, Teng MW, Smyth MJ. Ngiow SF, et al. Cancer Res. 2011 Nov 1;71(21):6567-71. doi: 10.1158/0008-5472.CAN-11-1487. Epub 2011 Oct 18. Cancer Res. 2011. PMID: 22009533 Review.

9

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD. O'Sullivan T, et al. Among authors: ngiow sf. J Exp Med. 2012 Sep 24;209(10):1869-82. doi: 10.1084/jem.20112738. Epub 2012 Aug 27. J Exp Med. 2012. PMID: 22927549 Free PMC article.

10

Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.

Paget C, Duret H, Ngiow SF, Kansara M, Thomas DM, Smyth MJ. Paget C, et al. Among authors: ngiow sf. Oncoimmunology. 2012 Nov 1;1(8):1313-1322. doi: 10.4161/onci.21680. Oncoimmunology. 2012. PMID: 23243595 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page